mobile-logo
 

All News

14 Jul

Physiomics Technology in continued and expanded support of Lilly’s Oncology Programs

by 16by9
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology. Financial details of this agreement have not been disclosed. This follows the successful completion earlier this year...

Read More
13 Feb

Physiomics to present on Chronotherapy at the Annual Meeting of American Association of Cancer Research (“AACR”)

by 16by9
in Investor News / RNS
Comments

Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the 2008 AACR Annual Meeting, taking place in San Diego, on 12-16 April 2008. Dr Eric Fernandez will present a development update on the Company’s chronotherapy research program, as part of the EU funded TEMPO (Temporal Genomics for Tailored Chronotherapeutics) project. The abstract will be published...

Read More
17 Dec

MOU with Swansea University (access to Supercomputer “Blue C”)

by 16by9
in Other News
Comments

Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it has signed a Memorandum of Understanding ('MOU') with the Institute of Life Science of Swansea University, which will provide mutual benefits. Under the terms of the MOU, Physiomics will have access to the Supercomputer “Blue C”, one of the most powerful computers in the world dedicated to Life Science and...

Read More
12 Dec

Physiomics Collaboration Update – Cancer Cell Death Model Developed

by 16by9
in Investor News / RNS
Comments

ValiRx, the cancer therapeutics company, today announces that Phase 1 of its collaboration with Physiomics plc, the European systems biology simulation company, has been completed. Under the collaboration, originally announced in February 2007, Physiomics’ In Silico simulation technology has been successfully coupled with ValiRx’s GeneICE technology to generate a cancer cell death model – the Apoptosis Model....

Read More